VVT Med Signs $3.7 Million Distribution Agreement in India, Achieves European Sales Milestone and Announces Proposed Debt Settlement

VANCOUVER, BC, Nov. 11, 2025 /CNW/ - VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a leader in next-generation, minimally invasive, non-thermal, and non-tumescent ("NT-NT") solutions for venous disease, is pleased to announce several milestones in the execution of its stated global expansion, sales and capital strategies.

$3.7 Million Distribution Agreement in India

VVT Med has entered into a five-year distribution agreement dated September 5, 2025 with Medworks India, a leading healthcare distributor in India, for its ScleroSafe^™ medical device in the varicose vein treatment market (the "Distribution Agreement").

The Distribution Agreement commits Medworks India to purchase CAD $3.7 million worth of ScleroSafe^™ units over a five-year period, with CAD $1.85 million under a "Buy & Pay" model, subject to the early termination of the Distribution Agreement. The Company's ScleroSafe^™ received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) under Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India in 2022.

The Distribution Agreement will be in effect for five years from the effective date, unless terminated earlier or extended through a written mutual amendment. The Company may terminate the agreement for cause, including payment defaults, failure to meet obligations or sales targets, legal changes, IP disputes, or certain organizational changes within Medworks India. Either party may also terminate the agreement for convenience with 30 days' notice.

Following several dozen successful procedures performed across key vein centers, physician satisfaction has been high, resulting in confirmed reorders. Medworks has already placed its initial stocking order, marking the beginning of commercial rollout and physician adoption across India

"This partnership underscores Medworks India's confidence in the commercial potential of ScleroSafe^™. It is another important step in our global commercialization strategy and reflects the accelerating demand for our innovative NT-NT venous-care solution," said Erez Tetro, Chief Executive Officer of VVT Med Inc.

Clinical Milestone in Europe

The Company announced that, in collaboration with Promedika, its exclusive local representative, it has completed 150 ScleroSafe^™ treatments in North Macedonia. This number of procedures provides meaningful evidence of efficacy under the product's European Union CE certification and marks an important step toward broader adoption across the European Economic Area (EEA).

The milestone reflects recurring orders from the treating clinic, indicating consistent physician use and positive patient outcomes. Promedika has placed additional replenishment orders, and further orders are expected as adoption continues to grow.

The milestone was achieved under the leadership of Dr. Sasko Nikolov, a leading Interventional Cardiologist, who has been instrumental in expanding the use of ScleroSafe^™ in advanced and complex venous cases.

"ScleroSafe is my preferred technology for treating varicose veins, particularly in complex cases such as ulcers, recurrences, and advanced disease," said Dr. Sasko Nikolov

Debt Settlement to Strengthen Capital Structure

VVT Med is pleased to announce that it intends to issue 320,000 common shares at a deemed price of CAD$0.56 per share as compensation for advisory services rendered by certain consultants in connection with its public listing (the "Shares for Services"). In addition, the Company intends to enter into agreements with various vendors to settle up to CAD$720,197 of outstanding indebtedness through the issuance of up to 1,745,151 common shares at a price equal to the market price of CAD$0.31 per share (the "Proposed Debt Settlement").

The issuance of shares pursuant to the Shares for Services arrangement and the Proposed Debt Settlement is subject to approval by the TSX Venture Exchange (the "TSXV"). The shares will be subject to a statutory hold period of four months and one day, in accordance with applicable securities laws and TSXV policies.

Completion of the Proposed Debt Settlement remains conditional upon the execution of definitive agreements and receipt of final approval from the TSXV.

About VVT Med Inc.

VVT Medical develops, manufactures, and distributes minimally invasive, non-thermal, non-tumescent (NT-NT) solutions for the treatment of vein diseases, starting with varicose veins. VVT's FDA-cleared and CE-marked catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures with no anesthesia, no downtime, and minimal pain and side effects. Addressing the widest range of vein diameters, VVT's solutions empower patients by treating both the medical and aesthetic aspects of vein disease, while enabling physicians to deliver effective, efficient, and cost-saving treatments through proprietary, simultaneous sclerosant injection and blood aspiration.

Cautionary Note Regarding Forward-Looking Statements

This news release contains statements that constitute "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions, or that events or conditions "will," "would," "may," "could," or "should" occur.

Forward-looking statements in this news release include statements relating to the Company's expectations regarding the execution and impact of its global expansion, sales, and capital strategies; anticipated revenue and market penetration under the distribution agreement with Medworks India; expectations regarding physician adoption and recurring orders in India and Europe; the anticipated benefits of the clinical milestone in North Macedonia; the Company's intention to complete the Proposed Debt Settlement and issue shares for services; and the Company's ability to obtain TSXV approval for the issuance of shares. These statements reflect the current views of the Company and are based on assumptions and expectations about future events, including successful execution of distribution and commercialization agreements, continued physician adoption of ScleroSafe^™, regulatory approvals, and the Company's ability to meet TSXV requirements.

By their nature, forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks include the possibility that anticipated distribution and commercialization agreements may not generate expected revenue or market penetration; physician adoption may not continue as projected; regulatory or TSXV approvals may be delayed or not obtained; operational and financial risks, including the need for additional financing; and general market conditions and volatility that may affect the Company's securities regardless of operating performance.

The forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. Readers should not place undue reliance on forward-looking statements and should not rely upon this information as of any other date. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States. The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE VVT MED INC.

Media Contact: Orly Efraty, VP Global Marketing, E: [email protected], T: [phone]; Investor Contact: I3 Capital Inc., [email protected]